KTE-X19治疗复发或难治性成人B细胞急性淋巴细胞白血病:单臂、开放标签、多中心ZUMA-3研究2期结果
ZUMA-3是一项国际多中心、单臂、开放标签2期研究,评估自体抗CD19 CAR T细胞疗法KTE-X19在复发或难治性B前体急性淋巴细胞白血病成人患者中的疗效与安全性。55例接受治疗患者中,中位随访16.4个月时39例(71%;95%CI 57-82,p<0.0001)达到完全缓解或伴血液学不完全恢复的完全缓解,其中31例(56%)达到完全缓解。缓解者中38例(97%)微小残留病灶阴性,中位总生存未达到。≥3级不良事件最常见为贫血(49%)和发热(36%),≥3级细胞因子释放综合征24%、≥3级神经系统事件25%,发生2例5级KTE-X19相关事件(脑疝和脓毒性休克)。作者认为KTE-X19可能为这类患者带来长期临床获益。
要点
- 55例接受KTE-X19治疗患者中,39例(71%;95%CI 57-82,p<0.0001)达到完全缓解或伴血液学不完全恢复的完全缓解,其中31例(56%)为完全缓解。
- 缓解者中38例(97%)达到微小残留病灶阴性,中位总生存未达到;中位缓解持续时间12.8个月(95%CI 8.7-不可估计),中位无复发生存11.6个月(95%CI 2.7-15.5),中位总生存18.2个月(95%CI 15.9-不可估计)。
- ≥3级细胞因子释放综合征发生于13例(24%),≥3级神经系统事件发生于14例(25%),需在床旁识别并处理。
- ≥3级感染发生于14例(25%);发生2例5级KTE-X19相关事件(脑疝和脓毒性休克)。
- 10例(18%)患者在KTE-X19输注后接受异基因干细胞移植巩固。
适用人群与场景
- 年龄≥18岁、东部肿瘤协作组体能状态0-1分、骨髓形态学疾病(原始细胞>5%)的复发或难治性B前体急性淋巴细胞白血病成人患者。
- 研究在美国、加拿大和欧洲的25个中心入组。
诊断标准与关键阈值
- 入组要求骨髓形态学疾病(原始细胞>5%)。
- 疗效和安全性分析在治疗人群(所有接受一剂KTE-X19的患者)中进行。
处置流程与药物剂量
- 白细胞分离和预处理化疗后,单次输注KTE-X19 1×10^6 CAR T细胞/kg体重。
- 10例(18%)患者在KTE-X19输注后接受异基因干细胞移植巩固。
红旗征与不能漏的情况
- ≥3级细胞因子释放综合征发生于13例(24%)患者。
- ≥3级神经系统事件发生于14例(25%)患者。
- ≥3级感染发生于14例(25%)患者。
- 发生2例5级KTE-X19相关事件(脑疝和脓毒性休克)。
研究设计与关键结果
- 研究类型:国际、多中心、单臂、开放标签2期研究;2018年10月1日至2019年10月9日入组71例患者并接受白细胞分离,KTE-X19成功制备65例(92%),给药55例(77%);治疗患者中位年龄40岁(IQR 28-52)。
- 主要终点:中位随访16.4个月(13.8-19.6)时,39例(71%;95%CI 57-82,p<0.0001)达到完全缓解或伴血液学不完全恢复的完全缓解,其中31例(56%)达到完全缓解。
- 次要终点:中位缓解持续时间12.8个月(95%CI 8.7-不可估计),中位无复发生存11.6个月(95%CI 2.7-15.5),中位总生存18.2个月(95%CI 15.9-不可估计);缓解者中中位总生存未达到,38例(97%)微小残留病灶阴性;10例(18%)接受异基因干细胞移植巩固。
- 不良事件:≥3级最常见为贫血(27例[49%])和发热(20例[36%]);≥3级感染14例(25%);≥3级细胞因子释放综合征13例(24%);≥3级神经系统事件14例(25%);2例5级KTE-X19相关事件(脑疝和脓毒性休克)。
证据类型、等级与局限
- 证据类型:单臂、开放标签、多中心2期研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,KTE-X19在复发或难治性B前体急性淋巴细胞白血病成人患者中显示出高的完全缓解或伴血液学不完全恢复的完全缓解率,缓解者中位总生存未达到,安全性可控。
- 作者认为,这些发现表明KTE-X19可能为这类患者带来长期临床获益。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Despite treatment with novel therapies and allogeneic stem-cell transplant (allo-SCT) consolidation, outcomes in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia remain poor, underlining the need for more effective therapies.
METHODS: We report the pivotal phase 2 results of ZUMA-3, an international, multicentre, single-arm, open-label study evaluating the efficacy and safety of the autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy KTE-X19 in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia. Patients were enrolled at 25 sites in the USA, Canada, and Europe. Eligible patients were aged 18 years or older, with Eastern Cooperative Oncology Group performance status of 0-1, and morphological disease in the bone marrow (>5% blasts). After leukapheresis and conditioning chemotherapy, patients received a single KTE-X19 infusion (1 × 106 CAR T cells per kg bodyweight). The primary endpoint was the rate of overall complete remission or complete remission with incomplete haematological recovery by central assessment. Duration of remission and relapse-free survival, overall survival, minimal residual disease (MRD) negativity rate, and allo-SCT rate were assessed as secondary endpoints. Efficacy and safety analyses were done in the treated population (all patients who received a dose of KTE-X19). This study is registered with ClinicalTrials.gov, NCT02614066.
FINDINGS: Between Oct 1, 2018, and Oct 9, 2019, 71 patients were enrolled and underwent leukapheresis. KTE-X19 was successfully manufactured for 65 (92%) patients and administered to 55 (77%). The median age of treated patients was 40 years (IQR 28-52). At the median follow-up of 16·4 months (13·8-19·6), 39 patients (71%; 95% CI 57-82, p<0·0001) had complete remission or complete remission with incomplete haematological recovery, with 31 (56%) patients reaching complete remission. Median duration of remission was 12·8 months (95% CI 8·7-not estimable), median relapse-free survival was 11·6 months (2·7-15·5), and median overall survival was 18·2 months (15·9-not estimable). Among responders, the median overall survival was not reached, and 38 (97%) patients had MRD negativity. Ten (18%) patients received allo-SCT consolidation after KTE-X19 infusion. The most common adverse events of grade 3 or higher were anaemia (27 [49%] patients) and pyrexia (20 [36%] patients). 14 (25%) patients had infections of grade 3 or higher. Two grade 5 KTE-X19-related events occurred (brain herniation and septic shock). Cytokine release syndrome of grade 3 or higher occurred in 13 (24%) patients and neurological events of grade 3 or higher occurred in 14 (25%) patients.
INTERPRETATION: KTE-X19 showed a high rate of complete remission or complete remission with incomplete haematological recovery in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia, with the median overall survival not reached in responding patients, and a manageable safety profile. These findings indicate that KTE-X19 has the potential to confer long-term clinical benefit to these patients.
FUNDING: Kite, a Gilead Company.
参考来源
- Shah BD, Ghobadi A, Oluwole OO, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021. PMID: 34097852. doi:10.1016/S0140-6736(21)01222-8
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。